X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24269) 24269
Book Review (3875) 3875
Publication (2118) 2118
Conference Proceeding (305) 305
Book Chapter (111) 111
Dissertation (24) 24
Magazine Article (17) 17
Web Resource (10) 10
Trade Publication Article (5) 5
Newspaper Article (4) 4
Paper (4) 4
Book / eBook (2) 2
Data Set (2) 2
Presentation (2) 2
Reference (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (20424) 20424
index medicus (17054) 17054
humans (16238) 16238
female (9570) 9570
oncology (8291) 8291
male (8165) 8165
middle aged (6877) 6877
aged (6466) 6466
ophthalmology (6047) 6047
chemotherapy (4800) 4800
angiogenesis inhibitors - therapeutic use (4721) 4721
cancer (4577) 4577
adult (4494) 4494
treatment outcome (4400) 4400
antibodies, monoclonal, humanized (4122) 4122
endothelial growth-factor (4037) 4037
vascular endothelial growth factor a - antagonists & inhibitors (3924) 3924
vascular endothelial growth factor (3803) 3803
angiogenesis (3431) 3431
antineoplastic combined chemotherapy protocols - therapeutic use (3403) 3403
ranibizumab (2996) 2996
aged, 80 and over (2932) 2932
angiogenesis inhibitors - administration & dosage (2923) 2923
care and treatment (2919) 2919
therapy (2728) 2728
retrospective studies (2606) 2606
intravitreal injections (2517) 2517
animals (2479) 2479
antibodies, monoclonal - therapeutic use (2419) 2419
macular degeneration (2417) 2417
metastasis (2162) 2162
antibodies, monoclonal - administration & dosage (2094) 2094
colorectal cancer (2061) 2061
medicine & public health (2057) 2057
antibodies, monoclonal, humanized - administration & dosage (2040) 2040
antibodies, monoclonal, humanized - therapeutic use (2005) 2005
survival (1902) 1902
vegf (1902) 1902
research (1898) 1898
antineoplastic agents - therapeutic use (1793) 1793
follow-up studies (1780) 1780
trial (1760) 1760
colorectal neoplasms - drug therapy (1759) 1759
drug therapy (1730) 1730
surgery (1724) 1724
tomography, optical coherence (1724) 1724
disease-free survival (1676) 1676
pharmacology & pharmacy (1637) 1637
prognosis (1636) 1636
analysis (1634) 1634
angiogenesis inhibitors - adverse effects (1634) 1634
eye diseases (1601) 1601
angiogenesis inhibitors (1578) 1578
tumors (1545) 1545
fluorescein angiography (1518) 1518
intravitreal bevacizumab (1490) 1490
patients (1458) 1458
clinical trials (1423) 1423
colorectal neoplasms - pathology (1376) 1376
visual acuity (1355) 1355
prospective studies (1340) 1340
bevacizumab - administration & dosage (1287) 1287
expression (1285) 1285
genetic structures (1267) 1267
antineoplastic agents (1252) 1252
antineoplastic combined chemotherapy protocols - adverse effects (1235) 1235
fluorouracil (1218) 1218
cetuximab (1210) 1210
neovascularization (1201) 1201
combination (1198) 1198
bevacizumab - therapeutic use (1194) 1194
antimitotic agents (1193) 1193
visual acuity - physiology (1189) 1189
health aspects (1185) 1185
mice (1184) 1184
hematology, oncology and palliative medicine (1173) 1173
oxaliplatin (1156) 1156
avastin (1155) 1155
paclitaxel (1140) 1140
lung neoplasms - drug therapy (1138) 1138
abridged index medicus (1124) 1124
antibodies, monoclonal - adverse effects (1106) 1106
phase-ii trial (1094) 1094
1st-line treatment (1091) 1091
phase-iii trial (1078) 1078
neoplasm staging (1061) 1061
risk factors (1052) 1052
efficacy (1044) 1044
neoplasm metastasis (1040) 1040
cancer therapies (1038) 1038
leucovorin (1038) 1038
irinotecan (1032) 1032
sense organs (1030) 1030
injection (1028) 1028
article (1014) 1014
diabetic retinopathy (1013) 1013
vascular endothelial growth factor a - metabolism (1008) 1008
glioblastoma (1003) 1003
choroidal neovascularization - drug therapy (997) 997
combined modality therapy (997) 997
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22273) 22273
German (550) 550
French (520) 520
Japanese (376) 376
Korean (278) 278
Spanish (194) 194
Chinese (83) 83
Turkish (54) 54
Russian (52) 52
Czech (49) 49
Polish (48) 48
Hungarian (36) 36
Portuguese (34) 34
Italian (19) 19
Romanian (13) 13
Dutch (8) 8
Slovenian (6) 6
Croatian (5) 5
Finnish (5) 5
Slovak (4) 4
Swedish (4) 4
Hebrew (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Indonesian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


WHO Drug Information, ISSN 1010-9609, 07/2017, Volume 31, Issue 3, pp. 429 - 429
Avastin® Approval: FDA Use: Treatment of adult patients with certain colorectal, lung, brain, kidney and cervical cancers. Like Avastin®, Mvasi® caries a Boxed... 
Bevacizumab
Journal Article
European Journal of Cancer, ISSN 0959-8049, 08/2019, Volume 117, pp. 131 - 132
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Methylation | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 77, pp. 13 - 20
Abstract Purpose The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding and thromboembolism. To date, there is no biomarker... 
Hematology, Oncology and Palliative Medicine | Hypertension | Single-nucleotide polymorphism | Bevacizumab-associated toxicity | FOLFIRI/bevacizumab | Autophagy | Colorectal cancer | APOPTOSIS | INHIBITION | ONCOLOGY | SENESCENCE | STRESS | PLUS BEVACIZUMAB | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Middle Aged | Genotype | Male | Neoplasm Metastasis | Protein-Tyrosine Kinases - genetics | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Hypertension - chemically induced | Polymorphism, Single Nucleotide - genetics | Adult | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Autophagy - genetics | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Genetic aspects | Metastasis | Single nucleotide polymorphisms | Thromboembolism | Vascular endothelial growth factor | Medicine, Preventive | Preventive health services | Measurement | Endothelial growth factors | Blood pressure | Toxicity | Genes | Colorectal carcinoma | Clinical trials | Patients | Two phase | Bleeding | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Alleles | Phagocytosis | Genotypes | Polymorphism | Proteinuria | Cancer | Index Medicus
Journal Article
by Eadie, JA and Ip, MS
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, ISSN 0275-004X, 02/2016, Volume 36, Issue 2, pp. E10 - E12
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2018, Volume 24, Issue 17, pp. 4066 - 4071
The FDA approved niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial... 
TRIAL | ONCOLOGY | BEVACIZUMAB | BREAST
Journal Article
JOURNAL FRANCAIS D OPHTALMOLOGIE, ISSN 0181-5512, 01/2019, Volume 42, Issue 1, pp. E18 - E19
Journal Article
Ophthalmology, ISSN 0161-6420, 04/2019, Volume 126, Issue 4, pp. 639 - 641
Journal Article
Nature Medicine, ISSN 1078-8956, 06/2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Bioindicators | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2016, Volume 11, Issue 1, pp. e0148019 - e0148019
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 12/2018, Volume 125, Issue 12, pp. 1967 - 1968
Journal Article
Ophthalmology, ISSN 0161-6420, 2016, Volume 124, Issue 3, pp. 408 - 409
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, pp. e0134308 - e0134308
Anti-vascular endothelial growth factor (VEGF) agents are the mainstay treatment for various angiogenesis-related retinal diseases. Currently, bevacizumab, a... 
ENERGY | ANGIOGENESIS | PHARMACOKINETICS | SAFETY | MULTIDISCIPLINARY SCIENCES | RETINOPATHY | BEVACIZUMAB AVASTIN | NEOVASCULARIZATION | ENDOTHELIAL GROWTH-FACTOR | ADIPOSE-TISSUE | Bevacizumab - pharmacology | Bevacizumab - administration & dosage | Enzyme-Linked Immunosorbent Assay | Intravitreal Injections | Mice, Inbred C57BL | Autoantibodies - administration & dosage | Vascular Endothelial Growth Factor A - immunology | Autoantibodies - pharmacology | Autoantibodies - immunology | Adipose Tissue, Brown - chemistry | Animals | Fluorescent Antibody Technique | Animals, Newborn - anatomy & histology | Autoantibodies - analysis | Adipose Tissue, Brown - drug effects | Mice | Adipose Tissue, Brown - blood supply | Retinal Neovascularization - drug therapy | Real-Time Polymerase Chain Reaction | Vascular Endothelial Growth Factor A - physiology | Bevacizumab - immunology | Bevacizumab - analysis | Adipose tissues | Viral antibodies | Infants (Premature) | Body weight | Antibodies | Mitochondrial DNA | Vascular endothelial growth factor | Neonates | Diabetic retinopathy | Retinopathy | Adipose tissue | Laboratories | Homeostasis | Retina | Infants | Bevacizumab | Proteins | Angiogenesis | Mitochondria | Newborn babies | Rodents | Adipose tissue (brown) | Recombinant | Complications | Research & development--R&D | Medical treatment | Injection | Gene expression | Medicine | Hypoxia | Diabetes | Index Medicus | Research & development | R&D
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2016, Volume 27, Issue 1, pp. 140 - 147
Journal Article
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, ISSN 0721-832X, 07/2019, Volume 257, Issue 7, pp. 1571 - 1571
The IRB number of the published article was A-2015-016 (page 1512, 1st paragraph of the method section). 
Medical colleges | Bevacizumab
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article